LARIMAR THERAPEUTICS

Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results

14 Nov 2023 07:00:00 By Nasdaq GlobeNewswire

Larimar Therapeutics to Present at the Guggenheim 5th Annual Inflammation, Neurology & Immunology Conference

01 Nov 2023 16:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors

03 Oct 2023 16:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics to Present at the Citi 18th Annual BioPharma Conference

31 Aug 2023 16:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Reports Second Quarter 2023 Operating and Financial Results

10 Aug 2023 07:00:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Appoints Dr. Rusty Clayton as Chief Medical Officer

17 Jul 2023 16:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Set to Join Russell 3000® Index

21 Jun 2023 16:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Reports Preliminary Top-line Data from Phase 2 Trial’s 25 mg Cohort Showing Increases in Frataxin Levels in Patients with Friedreich’s Ataxia and First Quarter 2023 Financial Results

15 May 2023 07:00:00 By Nasdaq GlobeNewswire

Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days

28 Mar 2023 16:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Reports Fourth Quarter and Full Year 2022 Operating and Financial Results

14 Mar 2023 07:00:01 By Nasdaq GlobeNewswire

Larimar Therapeutics Appoints Dr. Gopi Shankar as Chief Development Officer

07 Feb 2023 16:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics to Present at the 34th Annual Piper Sandler Healthcare Conference

21 Nov 2022 16:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Reports Third Quarter 2022 Operating and Financial Results

10 Nov 2022 07:00:04 By Nasdaq GlobeNewswire

Larimar Therapeutics to Participate in the Guggenheim 4th Annual Immunology & Neurology Day

07 Nov 2022 16:05:01 By Nasdaq GlobeNewswire

Larimar Therapeutics Announces Issuance of U.S. Patent Providing Composition of Matter Protection for CTI-1601

20 Oct 2022 08:00:01 By Nasdaq GlobeNewswire

Larimar Therapeutics Announces Oral and Poster Presentations at the Upcoming International Congress for Ataxia Research

19 Oct 2022 16:05:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Announces Closing of Underwritten Offering and Full Exercise of Option to Purchase Additional Shares

16 Sep 2022 13:00:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Announces $70 Million Underwritten Offering

14 Sep 2022 07:04:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Announces FDA Clearance to Initiate the 25 mg Cohort of a Phase 2 Dose Exploration Trial of CTI-1601 in Friedreich’s Ataxia Patients

14 Sep 2022 07:01:00 By Nasdaq GlobeNewswire

Larimar Therapeutics Provides Updates on CTI-1601 Clinical Program Following a Type C Meeting with the U.S. Food and Drug Administration and Reports Second Quarter 2022 Operating and Financial Results

11 Aug 2022 16:05:03 By Nasdaq GlobeNewswire